Search results
Added:
1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more
Added:
2 years ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Added:
5 months ago
Navigate the complex landscape of coronary interventions following transcatheter aortic valve replacement with Dr Samineh Sehatbakhsh, addressing critical access challenges in an era of expanding TAVR indications.This essential presentation, part of the Complex Cases track, examines the growing clinical significance of post-TAVR coronary access as procedures expand to younger, lower-risk patients…
View more
TAVI in Pure AR
Added:
1 year ago
Case Report
Exploring Exercise-induced Long QT
Added:
6 months ago
Review Article
Start date:
May 02, 2024
Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder that presents with positional tachycardia, amongst many other symptoms. Evidence for treatment options remains limited, and there are a multitude of associated conditions with overlapping symptoms which can make the diagnosis and management of POTS a difficult experience for providers and patients alike.This broadcast…
View more
Added:
2 years ago
POTS-associated Conditions and Management Strategies
Video Series
Added:
10 months ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Added:
2 years ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more